Pancreatic adenocarcinosarcoma of monoclonal origin: A case report

Figure 1 Axial pancreas-enhanced computed tomography findings. A: A 2.2 cm low attenuated mass in the pancreas body with diffuse pancreas duct dilatation (white arrow: pancreatic head mass); B: A 1.3 cm low attenuated hepatic nodule in S5 (black arrow: hepatic mass).

Figure 2 Magnetic resonance imaging findings. A: A T1 weighted magnetic resonance imaging (MRI) revealed a 2.2 cm mild low signal intensity pancreatic body mass with diffuse distal pancreatic duct dilatation (arrow: hepatic mass in S5); B: An MRI in the arterial phase revealed a 1.3 cm round, peripheral enhanced mass in S5 of the liver (arrow: pancreatic head mass).

Figure 3 Pancreatic neoplasia biopsy. A: Dual disparate sarcomatous (right) and carcinomatous (left) components of the tumor [hematoxylin and eosin (HE) stain, × 100); B: Sarcomatous component (HE stain, × 400); C: Carcinomatous component (HE stain, × 200).

Figure 4 Immunohistopathology of the pancreatic tumor. A: A pancreatic biopsy revealed a sarcomatoid component (right) containing mesenchymal tumor cells and a carcinomatous component that gave rise to tumor glands (left) [pan-cytokeratin (CK) staining, × 40]; B: The sarcomatoid component from the liver was also positive for pan-CK (× 400); C: In the pancreatic biopsy, the sarcomatous component stained positive for vimentin (right) while the adenomatous component was negative for vimentin (left) (× 40); D: The sarcomatoid component from the liver stained positive for vimentin (× 400).